期刊论文详细信息
Journal of Diabetes & Metabolic Disorders
Protective effect of magnesium on renal function in STZ-induced diabetic rats
Mansoor Keshavarz1  Yaser Azizi1  Behjat Seifi1  Mehri Kadkhodaee1  Nepton Soltani3  Seyed Mohammad Tavangar2  Mohsen Parviz1  Mohammad Reza Parvizi1 
[1] Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;Department of Physiology, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
关键词: Oxidative stress;    Diabetic nephropathy;    Streptozocin;    Diabetes mellitus type 1;   
Others  :  1136144
DOI  :  10.1186/s40200-014-0084-3
 received in 2014-01-15, accepted in 2014-07-23,  发布年份 2014
PDF
【 摘 要 】

Background

Diabetic nephropathy is a serious complication of T1D (type one diabetes mellitus). Persistent hyperglycemia and subsequent hypomagnesemia is believed to develop kidney damage by activation of oxidative stress. We conducted this study to investigate the renoprotective effect of magnesium sulfate (MgSO4) on renal histopathology and oxidative stress in diabetic rats.

Methods

The study included 70 male rats. The animals were divided into seven groups: control (CRL), control receiving MgSO4 (CRL + Mg1 & CRL + Mg8), diabetic (DM1 & DM8) and diabetic receiving MgSO4 (DM + Mg1 & DM + Mg8). Rats were given 20 mg/kg (i.p) Streptozocin (STZ) for 5 consecutive days in (MLD) multiple low doses to induce T1D. At day 10 treatment groups were received MgSO4 (10 g/l) in drinking water, for 1 or 8 weeks. The blood glucose, BUN and creatinine levels were measured. Renal tissue levels of malondialdehyde (MDA) were measured by thiobarbituric acid (TBA) method to evaluate the oxidative stress. Renal histopathology was done using H & E staining method.

Results

Treatment with MgSO4 significantly decreased the blood glucose in DM + Mg1 and DM + Mg8 groups as compared with DM1 and DM8. Magnesium treatment also decreased serum BUN and tissue level of MDA significantly in both short and long term treatment. The body weight loss and kidney weight to body weight ratio was improved by MgSO4. Histological results showed there were no differences between DM and DM + Mg groups.

Conclusion

Our findings showed that diabetic nephropathy is associated with high blood glucose level and oxidative stress (significant increase in MDA level). The renal dysfunction and oxidative stress can be improved by magnesium sulfate administration. It is suggested that protection against development of diabetic nephropathy by MgSO4 treatment involves changes in the blood glucose and oxidative stress.

【 授权许可】

   
2014 Parvizi et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150311122724446.pdf 1548KB PDF download
Figure 8. 136KB Image download
Figure 7. 14KB Image download
Figure 6. 20KB Image download
Figure 5. 17KB Image download
Figure 4. 16KB Image download
Figure 3. 18KB Image download
Figure 2. 15KB Image download
Figure 1. 17KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】
  • [1]Lu HJ, Tzeng TF, Hsu JC, Kuo SH, Chang CH, Huang SY, Chang FY, Wu MC, Liu IM: An aqueous-ethanol extract of liriope spicata var. prolifera ameliorates diabetic nephropathy through suppression of renal inflammation. Evid Based Complement Alternat Med 2013, 2013:201643. Epub 2013/09/13
  • [2]Schena FP, Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005, 16(Suppl 1):S30-S33. Epub 2005/06/07
  • [3]Ribeiro MC, Avila DS, Barbosa NB, Meinerz DF, Waczuk EP, Hassan W, Rocha JB: Hydrochlorothiazide and high-fat diets reduce plasma magnesium levels and increase hepatic oxidative stress in rats. Magnes Res 2013, 26(1):32-40. Epub 2013/05/10
  • [4]Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28(1):164-176. Epub 2004/12/24
  • [5]Kumawat M, Sharma TK, Singh I, Singh N, Ghalaut VS, Vardey SK, Shankar V: Antioxidant enzymes and lipid peroxidation in type 2 diabetes mellitus patients with and without nephropathy. N Am J Med Sci 2013, 5(3):213-219. Epub 2013/04/30
  • [6]Hans CP, Chaudhary DP, Bansal DD: Magnesium deficiency increases oxidative stress in rats. Indian J Exp Biol 2002, 40(11):1275-1279. Epub 2003/09/19
  • [7]Walti MK, Zimmermann MB, Spinas GA, Jacob S, Hurrell RF: Dietary magnesium intake in type 2 diabetes. Eur J Clin Nutr 2002, 56(5):409-414. Epub 2002/05/10
  • [8]Del Rio D, Stewart AJ, Pellegrini N: A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005, 15(4):316-328. Epub 2005/08/02
  • [9]Uchida K: Lipofuscin-like fluorophores originated from malondialdehyde. Free Radic Res 2006, 40(12):1335-1338. Epub 2006/11/09
  • [10]Kamper M, Tsimpoukidi O, Chatzigeorgiou A, Lymberi M, Kamper EF: The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Transl Res 2010, 156(1):26-36. Epub 2010/07/14
  • [11]Srivastava S, Chandrasekar B, Bhatnagar A, Prabhu SD: Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am J Physiol Heart Circ Physiol 2002, 283(6):H2612-H2619. Epub 2002/10/22
  • [12]Li B, Tan Y, Sun W, Fu Y, Miao L, Cai L: The role of zinc in the prevention of diabetic cardiomyopathy and nephropathy. Toxicol Mech Methods 2013, 23(1):27-33. Epub 2012/10/09
  • [13]Kisters K, Gremmler B, Kozianka J, Hausberg M: Magnesium deficiency and diabetes mellitus. Clin Nephrol 2006, 65(1):77-78. Epub 2006/01/25
  • [14]Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, Kawabata H, Niihata K, Okada N, Isaka Y, Rakugi H, Tsubakihara Y: Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care 2012, 35(7):1591-1597. Epub 2012/04/14
  • [15]Prabodh S, Prakash DS, Sudhakar G, Chowdary NV, Desai V, Shekhar R: Status of copper and magnesium levels in diabetic nephropathy cases: a case–control study from South India. Biol Trace Elem Res 2011, 142(1):29-35. Epub 2010/06/17
  • [16]Dasgupta A, Sarma D, Saikia UK: Hypomagnesemia in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012, 16(6):1000-1003. Epub 2012/12/12
  • [17]Scibior A, Golebiowska D, Niedzwiecka I: Magnesium can protect against vanadium-induced lipid peroxidation in the hepatic tissue. Oxid Med Cell Longev 2013, 2013:802734. Epub 2013/06/15
  • [18]Maksimovic-Ivanic D, Trajkovic V, Miljkovic DJ, Mostarica Stojkovic M, Stosic-Grujicic S: Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. Clin Exp Immunol 2002, 129(2):214-223. Epub 2002/08/08
  • [19]Soltani N, Keshavarz M, Sohanaki H, Zahedi Asl S, Dehpour AR: Relaxatory effect of magnesium on mesenteric vascular beds differs from normal and streptozotocin induced diabetic rats. Eur J Pharmacol 2005, 508(1–3):177-181. Epub 2005/02/01
  • [20]Soltani N, Keshavarz M, Minaii B, Mirershadi F, Zahedi Asl S, Dehpour AR: Effects of administration of oral magnesium on plasma glucose and pathological changes in the aorta and pancreas of diabetic rats. Clin Exp Pharmacol Physiol 2005, 32(8):604-610. Epub 2005/08/27
  • [21]Kojima N, Slaughter TN, Paige A, Kato S, Roman RJ, Williams JM: Comparison of the development diabetic induced renal disease in strains of Goto-Kakizaki rats.J Diabetes Metab 2013, Suppl 9(5). Epub 2013/12/10.
  • [22]Tesch GH, Allen TJ: Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007, 12(3):261-266. Epub 2007/05/15
  • [23]Cheng MF, Chen LJ, Cheng JT: Decrease of Klotho in the kidney of streptozotocin-induced diabetic rats. J Biomed Biotechnol 2010, 2010:513853. Epub 2010/07/14
  • [24]Baig MA, Gawali VB, Patil RR, Naik SR: Protective effect of herbomineral formulation (Dolabi) on early diabetic nephropathy in streptozotocin-induced diabetic rats. J Nat Med 2012, 66(3):500-509. Epub 2011/11/26
  • [25]Esterbauer H, Zollner H: Methods for determination of aldehydic lipid peroxidation products. Free Radic Biol Med 1989, 7(2):197-203. Epub 1989/01/01
  • [26]Esterbauer H, Cheeseman KH: Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990, 186:407-421. Epub 1990/01/01
  • [27]Esterbauer H, Dieber-Rotheneder M, Waeg G, Puhl H, Tatzber F: Endogenous antioxidants and lipoprotein oxidation. Biochem Soc Trans 1990, 18(6):1059-1061. Epub 1990/12/01
  • [28]Zafar M, Naeem-ul-Hassan Naqvi S: Effects of STZ-induced diabetes on the relative weights of kidney, liver and pancreas in albino rats: a comparative study. Int J Morphol 2010, 28:135-142.
  • [29]Pan HZ, Zhang L, Guo MY, Sui H, Li H, Wu WH, Qu NQ, Liang MH, Chang D: The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol 2010, 47(Suppl 1):71-76. Epub 2009/05/29
  • [30]Eid S, Maalouf R, Jaffa AA, Nassif J, Hamdy A, Rashid A, Ziyadeh FN, Eid AA: 20-HETE and EETs in diabetic nephropathy: a novel mechanistic pathway. PLoS One 2013, 8(8):e70029. Epub 2013/08/13
  • [31]Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL: Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005, 54(Suppl 2):S97-S107. Epub 2005/11/25
  • [32]Soltani N, Keshavarz M, Sohanaki H, Dehpour AR, Zahedi Asl S: Oral magnesium administration prevents vascular complications in STZ-diabetic rats. Life Sci 2005, 76(13):1455-1464. Epub 2005/02/01
  • [33]Kim DJ, Xun P, Liu K, Loria C, Yokota K, Jacobs DR Jr, He K: Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 2010, 33(12):2604-2610. Epub 2010/09/03
  • [34]de Araujo M, Andrade L, Coimbra TM, Rodrigues AC Jr, Seguro AC: Magnesium supplementation combined with N-acetylcysteine protects against postischemic acute renal failure. J Am Soc Nephrol 2005, 16(11):3339-3349. Epub 2005/09/24
  • [35]Anetor JI, Senjobi A, Ajose OA, Agbedana EO: Decreased serum magnesium and zinc levels: atherogenic implications in type-2 diabetes mellitus in Nigerians. Nutr Health 2002, 16(4):291-300. Epub 2003/03/06
  • [36]Laires MJ, Monteiro CP, Bicho M: Role of cellular magnesium in health and human disease. Front Biosci 2004, 9:262-276. Epub 2004/02/10
  • [37]Balon TW, Gu JL, Tokuyama Y, Jasman AP, Nadler JL: Magnesium supplementation reduces development of diabetes in a rat model of spontaneous NIDDM. Am J Physiol 1995, 269(4 Pt 1):E745-E752. Epub 1995/10/01
  • [38]Solaimani H, Soltani N, MaleKzadeh K, Sohrabipour S, Zhang N, Nasri S, Wang Q: Modulation of GLUT4 expression by oral administration of Mg (2+) to control sugar levels in STZ-induced diabetic rats. Can J Physiol Pharmacol 2014, 92(6):438-444. Epub 2014/05/14
  • [39]Huang CY, Liou YF, Chung SY, Pai PY, Kan CB, Kuo CH, Tsai CH, Tsai FJ, Chen JL, Lin JY: Increased expression of glucose transporter 3 in gerbil brains following magnesium sulfate treatment and focal cerebral ischemic injury. Cell Biochem Funct 2010, 28(4):313-320. Epub 2010/06/03
  • [40]Laurant P, Touyz RM, Schiffrin EL: Effect of magnesium on vascular tone and reactivity in pressurized mesenteric resistance arteries from spontaneously hypertensive rats. Can J Physiol Pharmacol 1997, 75(4):293-300. Epub 1997/04/01
  • [41]Dabla PK: Renal function in diabetic nephropathy. World J Diabetes 2010, 1(2):48-56. Epub 2011/05/04
  • [42]Avram MM, Hurtado H: Renal size and function in diabetic nephropathy. Nephron 1989, 52(3):259-261. Epub 1989/01/01
  • [43]Kadkhodaee M, Mikaeili S, Zahmatkesh M, Golab F, Seifi B, Arab HA, Shams S, Mahdavi-Mazdeh M: Alteration of renal functional, oxidative stress and inflammatory indices following hepatic ischemia-reperfusion. Gen Physiol Biophys 2012, 31(2):195-202. Epub 2012/07/12
  • [44]Trujillo J, Chirino YI, Molina-Jijon E, Anderica-Romero AC, Tapia E, Pedraza-Chaverri J: Renoprotective effect of the antioxidant curcumin: Recent findings. Redox Biol 2013, 1(1):448-456. Epub 2013/11/06
  • [45]Sargin AK, Can B, Turan B: Comparative investigation of kidney mesangial cells from increased oxidative stress-induced diabetic rats by using different microscopy techniques. Mol Cell Biochem 2014, 390(1-2):41-49. Epub 2013 Dec 29
  • [46]Kim MJ, Lim Y: Protective effect of short-term genistein supplementation on the early stage in diabetes-induced renal damage. Mediators Inflamm 2013, 2013:510212. Epub 2013 Apr 29
  • [47]Yokozawa T, Yamabe N, Cho EJ, Nakagawa T, Oowada S: A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats. Nephron Exp Nephrol 2004, 97(2):e38-e48. Epub 2004/06/26
  • [48]Israa FJA, Huda Arif J: Role of Antioxidant on Nephropathy in Alloxan Induced Diabetes in Rabbits. Iraqi postgraduate Med J 2009, 8(4):398-402.
  • [49]Giannoukakis N, Rudert WA, Trucco M, Robbins PD: Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J Biol Chem 2000, 275(47):36509-36513. Epub 2000/09/01
  • [50]Niranjan G, Mohanavalli V, Srinivasan AR, Ramesh R: Serum lipid peroxides and magnesium levels following three months of treatment with pioglitazone in patients with Type 2 Diabetes mellitus. Diabetes Metab Syndr 2013, 7(1):35-37. Epub 2013/03/23
  • [51]Bhutia Y, Ghosh A, Sherpa ML, Pal R, Mohanta PK: Serum malondialdehyde level: Surrogate stress marker in the Sikkimese diabetics. J Nat Sci Biol Med 2011, 2(1):107-112. Epub 2011/01/01
  • [52]Scibior A, Gołębiowska D, Niedźwiecka I: Magnesium can protect against vanadium-induced lipid peroxidation in the hepatic tissue. Oxid Med Cell Longev 2013, 2013:11.
  • [53]Agarwal R, Iezhitsa IN, Agarwal P, Spasov AA: Mechanisms of cataractogenesis in the presence of magnesium deficiency. Magnes Res 2013, 26(1):2-8. Epub 2013/05/28
  • [54]Dunlop M: Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 2000, 77:S3-S12. Epub 2000/09/21
  • [55]Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K: Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999, 10(4):822-832. Epub 1999/04/15
  • [56]Malatiali S, Francis I, Barac-Nieto M: Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008, 2008:305403. Epub 2008/09/05
  • [57]Ren XJ, Guan GJ, Liu G, Zhang T, Liu GH: Effect of activin A on tubulointerstitial fibrosis in diabetic nephropathy. Nephrology (Carlton) 2009, 14(3):311-320. Epub 2009/03/21
  • [58]Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, Suzuki K, Tachikawa H, Kodama M, Aizawa Y: Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. Biol Pharm Bull 2009, 32(8):1411-1416. Epub 2009/08/05
  • [59]Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44(10):1139-1146. Epub 1995/10/01
  文献评价指标  
  下载次数:4次 浏览次数:11次